Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fufang Zhenshu Tiaozhi capsule (FTZ) is a patented traditional Chinese medicine (TCM) hospital preparation developed by Guangdong Pharmaceutical University for the treatment of glucolipid metabolic disorders (GLMDs). It is composed of eight herbal ingredients: Rhizoma Coptidis, Fructus Ligustri Lucidi, Herba Cirsii Japonici, Radix Salviae Miltiorrhizae, Radix Notoginseng, Cortex Eucommiae, Fructus Citri Sarcodactylis, and Radix Atractylodes Macrocephala. FTZ is clinically used to treat type 2 diabetes mellitus, coronary heart disease, nonalcoholic steatohepatitis (NASH), and diabetic kidney disease. It exerts its therapeutic effects through multiple mechanisms, including anti-inflammatory, anti-oxidative, and lipid-regulating activities, as well as modulating the gut-liver axis and inhibiting the SGLT2/glycolysis pathway.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fufang Zhenshu Tiaozhi capsule.